Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual MM09 for house dust mite allergic rhinitis/rhinoconjunctivitis with or without mild to moderate asthma
2023-505918-14-00Phase 3Authorised
- Sponsor
- Inmunotek
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma comparing Sublingual MM09 with Placebo (2 arms). Primary endpoint: Mean daily Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score. Planned start Jul 2025; status: authorised.
02
Drugs
Clustoid MM09
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2023-505918-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505918-14-00.